Navigation Links
TorreyPines Receives Notice of Delisting from Nasdaq Global Market

LA JOLLA, Calif., July 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced today that it had received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that it did not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5450(b)(1)(A), prior to the expiration of the extension granted by the Staff on July 14, 2009. TorreyPines initially received notification from the Staff of its noncompliance with the minimum $10,000,000 stockholders' equity requirement for continued listing on March 31, 2009.

The Company plans to request a hearing before the Nasdaq Listing Qualifications Panel to review the Staff determination to delist the Company's common stock. The request for a hearing will stay the Staff determination to delist the Company's common stock until the Panel renders a determination following the hearing. The hearing is expected to be scheduled within 30 to 45 days of the Company's request, which the Company will submit on July 21, 2009.

There can be no assurances that the Listing Qualifications Panel will grant the Company's request for continued listing on The Nasdaq Global Market, in which case the Company's common stock could be delisted from The Nasdaq Stock Market.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665 X125

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
2. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
3. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
4. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
5. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
8. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
9. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
10. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Cepheid (Nasdaq: ... ending September 30, 2015. --> ... total revenue for the third quarter of 2015 is ... per share is expected to be approximately $(0.32) for ... non-GAAP net loss per share for the third quarter ...
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , the ... cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 Research ... the "US & Europe Markets for Bone Morphogenetic ... report to their offering. --> ... factors that induce the formation of bone after a ... during embryonic development in the formation of the skeleton. ...
(Date:10/13/2015)... -- " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ... bn by 2023, expanding at a CAGR of 5.9% during the ... Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, ... global microbiology culture market was valued at US$4.51 bn in 2014 ...
Breaking Biology Technology:
(Date:9/28/2015)... , September 28, 2015 According ... (Hardware & Software), Product (Scanner & Others), Application (Access ... Defense, & Others) & Geography Global - Forecast to ... to reach USD 3627.90 Million by 2020, at a ... Browse 65 market data T ables and ...
(Date:9/24/2015)... 24, 2015 Publiceringsförbud ... Kerv ( ), ... idag världens första kontaktlösa betalningsring på ... 000 GBP för massproduktion via crowdfunding.  ... , Kerv-bärare kan göra direkta ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
Breaking Biology News(10 mins):